CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations

BACKGROUND: Chimeric antigen receptor T‐cell (CAR‐T) therapy for acute myeloid leukaemia (AML) has thus far been elusive, in part due to target restriction and phenotypic heterogeneity of AML cells. Mutations of the FMS‐like tyrosine kinase 3 (FLT3) and DNA methyltransferase 3A (DNMT3A) genes are co...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Ling, Huang, Hongming, Tang, Yutong, Li, Qing, Wang, Jue, Li, Dengju, Zhong, Zhaodong, Zou, Ping, You, Yong, Cao, Yang, Kong, Yingjie, Guo, Anyuan, Zhou, Shu, Li, Huimin, Meng, Fankai, Xiao, Yi, Zhu, Xiaojian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513046/
https://www.ncbi.nlm.nih.gov/pubmed/36163632
http://dx.doi.org/10.1002/ctm2.1043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513046/
https://www.ncbi.nlm.nih.gov/pubmed/36163632
http://dx.doi.org/10.1002/ctm2.1043

Ejemplares similares